Comera Life Sciences (NASDAQ:CMRA) & Zymeworks (NYSE:ZYME) Head-To-Head Survey

Comera Life Sciences (NASDAQ:CMRA) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

92.9% of Zymeworks shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 1.9% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Comera Life Sciences and Zymeworks”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00 million	0.00	-$18.00 million	($0.49)	0.00
Zymeworks	$134.48 million	10.30	-$118.67 million	($0.84)	-22.02

Comera Life Sciences has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Comera Life Sciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Profitability

This table compares Comera Life Sciences and Zymeworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Zymeworks	-182.75%	-23.00%	-18.04%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Comera Life Sciences and Zymeworks, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Comera Life Sciences	0	0	0	0	0.00
Zymeworks	0	1	7	0	2.88

Zymeworks has a consensus price target of $24.67, suggesting a potential upside of 33.33%. Given Zymeworks’ stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Comera Life Sciences.

About Comera Life Sciences

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.